Sickle Cell Disease - Pipeline Insight, 2018

  • ID: 4471030
  • Drug Pipelines
  • 142 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • Acceleron
  • AstraZeneca
  • DecImmune
  • Gilead Sciences
  • La Jolla
  • Novartis
  • MORE
"Sickle Cell Disease- Pipeline Insight, 2018" report outlays comprehensive Insight of present scenario and growth prospects across Sickle Cell Disease. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 55+ products along with 50+ companies involved.

Products covered by Phase
  • Phase III, Phase II, Phase I and IND
  • Pre-clinical and Discovery
  • Unknown Stage
  • Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Sickle Cell Disease

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Sickle Cell Disease

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • Provides an overview of therapeutic pipeline activity for Sickle Cell Disease across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Sickle Cell Disease therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Sickle Cell Disease
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Sickle Cell Disease to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Sickle Cell Disease R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Sickle Cell Disease to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acceleron
  • AstraZeneca
  • DecImmune
  • Gilead Sciences
  • La Jolla
  • Novartis
  • MORE
Sickle Cell Disease Overview
Causes
Symptoms
Pathophysiology
Types of Sickle Cell Disease
Diagnosis
Treatment
Research for Future Treatment
Pipeline Therapeutics (Clinical Products)
Pipeline Therapeutics (Non-Clinical Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Crizanlizumab: Novartis
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Unknown Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Drugs
Comparative Analysis
Discontinued Drugs
Comparative Analysis
Appendix

List of Tables:
Table 1: Total Products for Sickle Cell Disease
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I and IND)
Table 5: Pre-clinical and Discovery Stage Products
Table 6: Unknown Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Dormant Drugs
Table 13: Discontinued Drugs

List of Figures:
Figure 1: Formation of Sickled Red Blood Cell
Figure 2: Gene Modulation of Sickle Cell Disease
Figure 3: Pathophysiology of Sickle Cell Disease
Figure 4: Treatment (Therapy) and Management of SCD
Figure 5: Total Products for Sickle Cell Disease
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I and IND)
Figure 9: Pre-clinical and Discovery Stage Products
Figure 10: Unknown Stage Products
Figure 11: Assessment by Monotherapy Products
Figure 12: Assessment by Route of Administration
Figure 13: Assessment by Stage and Route of Administration
Figure 14: Assessment by Molecule Type
Figure 15: Assessment by Stage and Molecule Type
Figure 16: Dormant Drugs
Figure 17: Discontinued Drugs
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acceleron
  • Actelion
  • Addex Therapeutics
  • Advinus Therapeutics
  • AesRx
  • Angiocrine Bioscience
  • ArQule
  • Astellas
  • AstraZeneca
  • Bioverativ
  • Bluebird Bio
  • Bristol-Myers Squibb
  • Centocor
  • Complexa
  • CRISPR Therapeutics
  • CSL Behring
  • DecImmune
  • DeuteRx
  • Ebelle D'Ebelle Pharmaceuticals
  • Editas Medicine
  • Eli Lilly
  • EpimedX
  • Errant Gene Therapeutics
  • Gamida-Cell
  • Genethon
  • Gilead Sciences
  • Global Blood Therapeutics
  • Glycomimetics
  • HemaQuest Pharmaceuticals
  • Hillhurst Biopharmaceuticals
  • Icagen
  • Imara
  • Incyte
  • Ironwood
  • La Jolla
  • Leo Pharma
  • Mast Therapeutics
  • MaxCyte
  • Merganser Biotech
  • MimeTech
  • Modus Therapeutics
  • Molecules for Health
  • Novartis
  • NuvOx Pharma
  • Orphagen Pharmaceuticals
  • Pfizer
  • PharmaEssentia
  • Prolong Pharmaceuticals
  • Regenacy Pharmaceuticals
  • ReveraGen
  • Sancilio & Company
  • Sanofi
  • TRF Pharma
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll